{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:29Z","timestamp":1791478109972,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Zhuang Autonomous Region Health Commission","award":["Z20190285"],"award-info":[{"award-number":["Z20190285"]}]},{"name":"Liuzhou Science and Technology Bureau","award":["2022CAC0104"],"award-info":[{"award-number":["2022CAC0104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04034-6","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:55:40Z","timestamp":1737647740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Huasheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"2","key":"4034_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1152\/physrev.00010.2016","volume":"97","author":"J Dalmau","year":"2017","unstructured":"Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in Autoimmune diseases of the Central Nervous System. Physiol Rev. 2017;97(2):839\u201387.","journal-title":"PHYSIOL REV"},{"issue":"7","key":"4034_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosur Ps. 2021;92(7):757\u201368.","journal-title":"J NEUROL NEUROSUR PS"},{"issue":"Pt 10","key":"4034_CR3","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/brain\/aww208","volume":"139","author":"J Kreye","year":"2016","unstructured":"Kreye J, Wenke NK, Chayka M, Leubner J, Murugan R, Maier N, Jurek B, Ly LT, Brandl D, Rost BR, et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. 2016;139(Pt 10):2641\u201352.","journal-title":"Brain"},{"issue":"1","key":"4034_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ana.24195","volume":"76","author":"EH Moscato","year":"2014","unstructured":"Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;76(1):108\u201319.","journal-title":"ANN NEUROL"},{"issue":"3","key":"4034_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/abbs\/gmv135","volume":"48","author":"P Ju","year":"2016","unstructured":"Ju P, Cui D. The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia. Acta Bioch Bioph Sin. 2016;48(3):209\u201319.","journal-title":"ACTA BIOCH BIOPH SIN"},{"issue":"7","key":"4034_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal fc receptor. Nat Rev Immunol. 2023;23(7):415\u201332.","journal-title":"NAT REV IMMUNOL"},{"issue":"10","key":"4034_CR7","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, et al. Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J CLIN INVEST"},{"issue":"7","key":"4034_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JJ Howard","year":"2021","unstructured":"Howard JJ, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"LANCET NEUROL"},{"issue":"12","key":"4034_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/1744666X.2022.2136167","volume":"18","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Uzawa A, Murai H. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Expert Rev Clin Immu. 2022;18(12):1207\u201315.","journal-title":"EXPERT REV CLIN IMMU"},{"key":"4034_CR10","first-page":"1280218949","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Diso. 2021;14:1280218949.","journal-title":"THER ADV NEUROL DISO"},{"key":"4034_CR11","doi-asserted-by":"crossref","unstructured":"Huang SQ, Yuan ZH, Hong Y, Jiang T, Zhao HD, Shi JQ. Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report. Neurol Sci 2024.","DOI":"10.1007\/s10072-024-07678-3"},{"key":"4034_CR12","doi-asserted-by":"crossref","unstructured":"Zhu F, Wang WF, Ma CH, Liang H, Jiang YQ. Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod. J Neurol 2024.","DOI":"10.1007\/s00415-024-12556-1"},{"issue":"6","key":"4034_CR13","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","volume":"271","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ma J, Feng Y, Ma H, Liu D, Pang X, Chang X, Zhao R, Wang J, Guo J, et al. Efgartigimod in the treatment of Guillain-Barre syndrome. J Neurol. 2024;271(6):3506\u201311.","journal-title":"J NEUROL"},{"issue":"1","key":"4034_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25\u201336.","journal-title":"ANN NEUROL"},{"key":"4034_CR15","doi-asserted-by":"publisher","first-page":"577753","DOI":"10.1016\/j.jneuroim.2021.577753","volume":"361","author":"H Ren","year":"2021","unstructured":"Ren H, Fan S, Zhao Y, Guan H. The changing spectrum of antibody-mediated encephalitis in China. J Neuroimmunol. 2021;361:577753.","journal-title":"J NEUROIMMUNOL"},{"issue":"1","key":"4034_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/nyas.12553","volume":"1338","author":"F Leypoldt","year":"2015","unstructured":"Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann Ny Acad Sci. 2015;1338(1):94\u2013114.","journal-title":"ANN NY ACAD SCI"},{"issue":"3","key":"4034_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","volume":"75","author":"MJ Titulaer","year":"2014","unstructured":"Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, Benson LA, Shu H, Irioka T, Hirano M, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411\u201328.","journal-title":"ANN NEUROL"},{"issue":"1","key":"4034_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63\u201374.","journal-title":"LANCET NEUROL"},{"key":"4034_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.seizure.2015.04.005","volume":"29","author":"R Wang","year":"2015","unstructured":"Wang R, Guan HZ, Ren HT, Wang W, Hong Z, Zhou D. CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis. Seizure-Eur J Epilep. 2015;29:137\u201342.","journal-title":"SEIZURE-EUR J EPILEP"},{"key":"4034_CR20","doi-asserted-by":"crossref","unstructured":"Ciano-Petersen NL, Cabezudo-Garcia P, Muniz-Castrillo S, Honnorat J, Serrano-Castro PJ, Oliver-Martos B. Current status of biomarkers in Anti-N-Methyl-D-Aspartate receptor encephalitis. Int J Mol Sci 2021, 22(23).","DOI":"10.3390\/ijms222313127"},{"issue":"11","key":"4034_CR21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/acn3.444","volume":"4","author":"M Malviya","year":"2017","unstructured":"Malviya M, Barman S, Golombeck KS, Planaguma J, Mannara F, Strutz-Seebohm N, Wrzos C, Demir F, Baksmeier C, Steckel J, et al. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. Ann Clin Transl Neur. 2017;4(11):768\u201383.","journal-title":"ANN CLIN TRANSL NEUR"},{"key":"4034_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand K, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal fc receptor (FcRn): a Misnomer? Front Immunol. 2019;10:1540.","journal-title":"FRONT IMMUNOL"},{"issue":"4","key":"4034_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CND.0000000000000451","volume":"24","author":"M Jaffry","year":"2023","unstructured":"Jaffry M, Menkes DL, Shaikh A, Mandava K, Kothari O, Jaffry K, Souayah N. Neonatal fc receptor inhibitor therapeutics in Neuromuscular Disease. J Clin Neuromuscul Dis. 2023;24(4):188\u201398.","journal-title":"J Clin Neuromuscul Dis"},{"key":"4034_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jneuroim.2019.02.008","volume":"330","author":"B Deng","year":"2019","unstructured":"Deng B, Yu H, Liu X, Yu X, Zhang X, Li X, Yang W, Dong S, Qiu Y, Chen X. Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: an observation study in Chinese patients. J Neuroimmunol. 2019;330:81\u20136.","journal-title":"J NEUROIMMUNOL"},{"key":"4034_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2017.04.007","volume":"377","author":"BJ Wang","year":"2017","unstructured":"Wang BJ, Wang CJ, Zeng ZL, Yang Y, Guo SG. Lower dosages of Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. J Neurol Sci. 2017;377:127\u201332.","journal-title":"J NEUROL SCI"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04034-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:55:48Z","timestamp":1737647748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04034-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4034"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04034-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was was in accordance with the ethical standards of Liuzhou People\u2019s Hospital affiliated to Guangxi Medical University and with the Helsinki declaration. The patient provided written informed consent according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient gave written informed consent for their personal or clinical details to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}